接种新冠疫苗后的非典型皮下起泡病

IF 1.1 Q4 ALLERGY
Noureddine Litaiem MD, Azza Ghannem MD, Amal Chabbouh MD, Soumaya Rammeh MD, Maryam Sellami MD, Faten Zeglaoui MD
{"title":"接种新冠疫苗后的非典型皮下起泡病","authors":"Noureddine Litaiem MD,&nbsp;Azza Ghannem MD,&nbsp;Amal Chabbouh MD,&nbsp;Soumaya Rammeh MD,&nbsp;Maryam Sellami MD,&nbsp;Faten Zeglaoui MD","doi":"10.1002/cia2.12308","DOIUrl":null,"url":null,"abstract":"<p>Dear Editor,</p><p>Cutaneous bullous eruptions triggered after COVID-19 vaccination have been reported.<span><sup>1</sup></span> However, a few cases of these blistering disorders have shown an atypical immunological profile. We present a distinctive case of an acquired bullous eruption in a 79-year-old patient appearing days after COVID-19 booster vaccination shot.</p><p>A 79-year-old female patient, with no past medical history or regular drug intake presented with a new onset of pruritic cutaneous blisters appearing 1 week after COVID-19 vaccination booster shot. She received two shots of Sinovac-CoronaVac vaccine, and a third shot using Pfizer-BioNTech Vaccine. Physical examination revealed tense and hemorrhagic blisters on normal-appearing, purpuric or erythematous skin (Figure 1A–C). Lesions were symmetrically distributed on the upper and lower limbs and sparing oral and genital mucosa. Nikolsky's sign was positive on purpuric skin. Skin biopsies were repeatedly performed showing similar results (Figure 1D,E). Histopathological examination revealed subepidermal blisters with numerous necrotic keratinocytes and vacuolar degeneration of basal epidermal cells associated with a lymphocytic inflammatory infiltrate of the dermis with no eosinophils. Direct immunofluorescence examination showed marked intradermal deposits of IgG, IgM, IgA, C3, and C1q within necrotic keratinocytes of the epidermis (Figure 1F). Indirect immunofluorescence and ELISA Testing for anti-desmoglein1, anti-desmoglein3, anti-BP180, and anti-BP230 were negative. A complete blood count results including eosinophil count were within normal range. Lesions kept progressing for 8 months. The patient denied any drug intake or infection preceding disease onset or relapse. The diagnosis of subepidermal blistering disease triggered by COVID-19 vaccination was made. The patient received clobetasol ointment leading to temporary control of the disease. However, blisters relapsed days after treatment discontinuation and were similarly managed with topical corticosteroids.</p><p>Subepidermal bullous eruptions following vaccination represent an immune-mediated event related to nonspecific off-target immune response.<span><sup>1</sup></span> Bullous pemphigoid is the most frequently reported auto-immune blistering disorder appearing after COVID-19 vaccination.<span><sup>2</sup></span> Pemphigus was less frequently associated with vaccination.<span><sup>3</sup></span> Our patient was remarkable as she had a chronic and relapsing disease that failed to meet the diagnostic criteria of pemphigus, pemphigoid, or any other auto-immune blistering disorder.</p><p>A few cases of Steven-Johnson syndrome/Toxic epidermal necrosis have been reported in response to virotope antigens of the COVID-19 vaccine.<span><sup>4</sup></span> These virotopes are expressed on the keratinocyte surface. This leads to CD8<sup>+</sup> T lymphocyte activation and epidermal cell apoptosis with subepidermal detachment.<span><sup>4</sup></span> Kong et al.<span><sup>5</sup></span> described a case of subepidermal blistering eruption following Moderna vaccine showing marked necrotic keratinocytes. In these cases, DIF and IIF were not performed.</p><p>In our patient, the clinical presentation was not consistent with the diagnosis of Steven-Johnson syndrome/Toxic epidermal necrosis. The negativity of DIF and anti-BP180/BP230 clearly emphasizes the cellular-mediated response.</p><p>Five other cases of subepidermal bullous eruptions following COVID-19 vaccination with atypical clinical or immunopathological features similar to our patient were described (Table 1). Tomayko et al.<span><sup>1</sup></span> reported four cases of subepidermal blistering disorders with negative DIF and serum anti-BP180/anti-BP230 antibodies.</p><p>These findings may arguably raise concern over the possibility of a distinct variant of subepidermal blistering eruption induced by these newly developed mRNA vaccines. However, this association is still debated.<span><sup>6</sup></span> Although a coincidence cannot be excluded, the short delay suggests a close relation between COVID-19 vaccination and this bullous disorder. The autonomization of the disease as a chronic blistering disorder after the removal of the culprit trigger requires longitudinal follow-up.<span><sup>7</sup></span> There are no drawing conclusions about avoidance or possible vaccinations. Our patient refused the new vaccination.</p><p>The authors declare no conflict of interest.</p><p>Approval of the research protocol: No human participant was involved in this study.</p><p>Informed Consent: The patient provided informed consent for the publication of the images submitted with this article.</p><p>Registry and the Registration No.: N/A.</p><p>Animal Studies: N/A.</p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2023-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12308","citationCount":"0","resultStr":"{\"title\":\"Atypical subepidermal blistering disease following COVID-19 vaccination\",\"authors\":\"Noureddine Litaiem MD,&nbsp;Azza Ghannem MD,&nbsp;Amal Chabbouh MD,&nbsp;Soumaya Rammeh MD,&nbsp;Maryam Sellami MD,&nbsp;Faten Zeglaoui MD\",\"doi\":\"10.1002/cia2.12308\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Dear Editor,</p><p>Cutaneous bullous eruptions triggered after COVID-19 vaccination have been reported.<span><sup>1</sup></span> However, a few cases of these blistering disorders have shown an atypical immunological profile. We present a distinctive case of an acquired bullous eruption in a 79-year-old patient appearing days after COVID-19 booster vaccination shot.</p><p>A 79-year-old female patient, with no past medical history or regular drug intake presented with a new onset of pruritic cutaneous blisters appearing 1 week after COVID-19 vaccination booster shot. She received two shots of Sinovac-CoronaVac vaccine, and a third shot using Pfizer-BioNTech Vaccine. Physical examination revealed tense and hemorrhagic blisters on normal-appearing, purpuric or erythematous skin (Figure 1A–C). Lesions were symmetrically distributed on the upper and lower limbs and sparing oral and genital mucosa. Nikolsky's sign was positive on purpuric skin. Skin biopsies were repeatedly performed showing similar results (Figure 1D,E). Histopathological examination revealed subepidermal blisters with numerous necrotic keratinocytes and vacuolar degeneration of basal epidermal cells associated with a lymphocytic inflammatory infiltrate of the dermis with no eosinophils. Direct immunofluorescence examination showed marked intradermal deposits of IgG, IgM, IgA, C3, and C1q within necrotic keratinocytes of the epidermis (Figure 1F). Indirect immunofluorescence and ELISA Testing for anti-desmoglein1, anti-desmoglein3, anti-BP180, and anti-BP230 were negative. A complete blood count results including eosinophil count were within normal range. Lesions kept progressing for 8 months. The patient denied any drug intake or infection preceding disease onset or relapse. The diagnosis of subepidermal blistering disease triggered by COVID-19 vaccination was made. The patient received clobetasol ointment leading to temporary control of the disease. However, blisters relapsed days after treatment discontinuation and were similarly managed with topical corticosteroids.</p><p>Subepidermal bullous eruptions following vaccination represent an immune-mediated event related to nonspecific off-target immune response.<span><sup>1</sup></span> Bullous pemphigoid is the most frequently reported auto-immune blistering disorder appearing after COVID-19 vaccination.<span><sup>2</sup></span> Pemphigus was less frequently associated with vaccination.<span><sup>3</sup></span> Our patient was remarkable as she had a chronic and relapsing disease that failed to meet the diagnostic criteria of pemphigus, pemphigoid, or any other auto-immune blistering disorder.</p><p>A few cases of Steven-Johnson syndrome/Toxic epidermal necrosis have been reported in response to virotope antigens of the COVID-19 vaccine.<span><sup>4</sup></span> These virotopes are expressed on the keratinocyte surface. This leads to CD8<sup>+</sup> T lymphocyte activation and epidermal cell apoptosis with subepidermal detachment.<span><sup>4</sup></span> Kong et al.<span><sup>5</sup></span> described a case of subepidermal blistering eruption following Moderna vaccine showing marked necrotic keratinocytes. In these cases, DIF and IIF were not performed.</p><p>In our patient, the clinical presentation was not consistent with the diagnosis of Steven-Johnson syndrome/Toxic epidermal necrosis. The negativity of DIF and anti-BP180/BP230 clearly emphasizes the cellular-mediated response.</p><p>Five other cases of subepidermal bullous eruptions following COVID-19 vaccination with atypical clinical or immunopathological features similar to our patient were described (Table 1). Tomayko et al.<span><sup>1</sup></span> reported four cases of subepidermal blistering disorders with negative DIF and serum anti-BP180/anti-BP230 antibodies.</p><p>These findings may arguably raise concern over the possibility of a distinct variant of subepidermal blistering eruption induced by these newly developed mRNA vaccines. However, this association is still debated.<span><sup>6</sup></span> Although a coincidence cannot be excluded, the short delay suggests a close relation between COVID-19 vaccination and this bullous disorder. The autonomization of the disease as a chronic blistering disorder after the removal of the culprit trigger requires longitudinal follow-up.<span><sup>7</sup></span> There are no drawing conclusions about avoidance or possible vaccinations. Our patient refused the new vaccination.</p><p>The authors declare no conflict of interest.</p><p>Approval of the research protocol: No human participant was involved in this study.</p><p>Informed Consent: The patient provided informed consent for the publication of the images submitted with this article.</p><p>Registry and the Registration No.: N/A.</p><p>Animal Studies: N/A.</p>\",\"PeriodicalId\":15543,\"journal\":{\"name\":\"Journal of Cutaneous Immunology and Allergy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2023-06-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12308\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cutaneous Immunology and Allergy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cia2.12308\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cutaneous Immunology and Allergy","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cia2.12308","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

摘要

尊敬的编辑,有报道称,covid - 19疫苗接种后引发皮肤大疱性皮疹然而,这些水疱疾病的少数病例已显示出非典型的免疫概况。我们提出了一个独特的情况下,获得大疱性爆发在79岁的病人出现几天后covid - 19加强疫苗接种。79岁女性患者,无既往病史,无常规药物摄入,在接种新冠疫苗1周后出现瘙痒性皮肤水疱。她接种了两针SinovacCoronaVac疫苗,第三针辉瑞biontech疫苗。体格检查发现正常皮肤上有紧张和出血性水疱,呈紫癜
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Atypical subepidermal blistering disease following COVID-19 vaccination

Atypical subepidermal blistering disease following COVID-19 vaccination

Dear Editor,

Cutaneous bullous eruptions triggered after COVID-19 vaccination have been reported.1 However, a few cases of these blistering disorders have shown an atypical immunological profile. We present a distinctive case of an acquired bullous eruption in a 79-year-old patient appearing days after COVID-19 booster vaccination shot.

A 79-year-old female patient, with no past medical history or regular drug intake presented with a new onset of pruritic cutaneous blisters appearing 1 week after COVID-19 vaccination booster shot. She received two shots of Sinovac-CoronaVac vaccine, and a third shot using Pfizer-BioNTech Vaccine. Physical examination revealed tense and hemorrhagic blisters on normal-appearing, purpuric or erythematous skin (Figure 1A–C). Lesions were symmetrically distributed on the upper and lower limbs and sparing oral and genital mucosa. Nikolsky's sign was positive on purpuric skin. Skin biopsies were repeatedly performed showing similar results (Figure 1D,E). Histopathological examination revealed subepidermal blisters with numerous necrotic keratinocytes and vacuolar degeneration of basal epidermal cells associated with a lymphocytic inflammatory infiltrate of the dermis with no eosinophils. Direct immunofluorescence examination showed marked intradermal deposits of IgG, IgM, IgA, C3, and C1q within necrotic keratinocytes of the epidermis (Figure 1F). Indirect immunofluorescence and ELISA Testing for anti-desmoglein1, anti-desmoglein3, anti-BP180, and anti-BP230 were negative. A complete blood count results including eosinophil count were within normal range. Lesions kept progressing for 8 months. The patient denied any drug intake or infection preceding disease onset or relapse. The diagnosis of subepidermal blistering disease triggered by COVID-19 vaccination was made. The patient received clobetasol ointment leading to temporary control of the disease. However, blisters relapsed days after treatment discontinuation and were similarly managed with topical corticosteroids.

Subepidermal bullous eruptions following vaccination represent an immune-mediated event related to nonspecific off-target immune response.1 Bullous pemphigoid is the most frequently reported auto-immune blistering disorder appearing after COVID-19 vaccination.2 Pemphigus was less frequently associated with vaccination.3 Our patient was remarkable as she had a chronic and relapsing disease that failed to meet the diagnostic criteria of pemphigus, pemphigoid, or any other auto-immune blistering disorder.

A few cases of Steven-Johnson syndrome/Toxic epidermal necrosis have been reported in response to virotope antigens of the COVID-19 vaccine.4 These virotopes are expressed on the keratinocyte surface. This leads to CD8+ T lymphocyte activation and epidermal cell apoptosis with subepidermal detachment.4 Kong et al.5 described a case of subepidermal blistering eruption following Moderna vaccine showing marked necrotic keratinocytes. In these cases, DIF and IIF were not performed.

In our patient, the clinical presentation was not consistent with the diagnosis of Steven-Johnson syndrome/Toxic epidermal necrosis. The negativity of DIF and anti-BP180/BP230 clearly emphasizes the cellular-mediated response.

Five other cases of subepidermal bullous eruptions following COVID-19 vaccination with atypical clinical or immunopathological features similar to our patient were described (Table 1). Tomayko et al.1 reported four cases of subepidermal blistering disorders with negative DIF and serum anti-BP180/anti-BP230 antibodies.

These findings may arguably raise concern over the possibility of a distinct variant of subepidermal blistering eruption induced by these newly developed mRNA vaccines. However, this association is still debated.6 Although a coincidence cannot be excluded, the short delay suggests a close relation between COVID-19 vaccination and this bullous disorder. The autonomization of the disease as a chronic blistering disorder after the removal of the culprit trigger requires longitudinal follow-up.7 There are no drawing conclusions about avoidance or possible vaccinations. Our patient refused the new vaccination.

The authors declare no conflict of interest.

Approval of the research protocol: No human participant was involved in this study.

Informed Consent: The patient provided informed consent for the publication of the images submitted with this article.

Registry and the Registration No.: N/A.

Animal Studies: N/A.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.60
自引率
10.00%
发文量
69
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信